" class="no-js "lang="en-US"> Sian & Olivia from Owen Mumford on Medical Devices
Thursday, March 23, 2023

Breaking News

Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million Medtronic to Boost AI Innovation with New Platform Introduction Ionis Accounces FDA Advisory Committee Voted Unanimously for a Potential Accelerated Approval of Tofersen for SOD1-ALS Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease

March 9 2023

Sian Eden & Olivia Houselander, Owen Mumford, on Medical Devices

In this video, Sian Eden and Olivia Houselander from Owen Mumford, a medical device company, discuss their company’s approach to designing and manufacturing medical devices. They highlight the importance of user-centered design and the use of factor testing to ensure that their products are safe and easy to use for patients and healthcare professionals alike.

They also showcase several of their products at the Pharmapack event, including Aidaptus and UniSafe, which are injection devices designed to make self-injection easier and more comfortable for patients.

Overall, the video provides insight into Owen Mumford’s commitment to creating safe, user-friendly, and sustainable medical devices that improve the lives of patients and healthcare professionals.

 

  1. Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer

    News

     Read more
  2. BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases

    Diseases

     Read more
  3. Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

    Drug Development

     Read more
  4. Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

    News

     Read more
  5. Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President

    Appointments

     Read more
More On